In April 1989, Drs Meduri, Conoscenti, Menashe, and Nair published the first report on noninvasive (intermittent) positive-pressure (mechanical) ventilation (NPPV) in patients with acute respiratory failure (ARF) in CHEST. 1 Six patients with hypercapnic ARF (all from COPD) and four with hypoxemic ARF (two from acute decompensated heart failure [ADHF] and two from ARDS) met clinical and objective criteria for mechanical ventilation, which was delivered with pressure control or pressure support via a tightly strapped, clear anesthesia face mask. Patients with ADHF and ARDS also received CPAP. No patient left the study because of inability to deliver adequate ventilation or to improve hypoxemia; three eventually required endotracheal intubation. 1 At the time, invasive mechanical ventilation was the exclusive approach in almost all cases of ARF with the exception of a few reports on mask CPAP in patients with hypoxemic ARF. 2 Despite documentation of a high incidence of complications related to intubation, prevailing opinion held that ventilatory support without airway control was unacceptable because of unpredictable tidal volumes and the risk for aspiration. 2 The introduction of NPPV in ARF would have a dramatic positive impact on critical care, and eventually become standard practice worldwide.
As authors of the original report, here we briefly review how the concept of NPPV originated and was tested. First, a charismatic leader created the fertile soil. Dr Sreedhar Nair (Chief, Section of Pulmonary Medicine and founder of the Hinds Center for Respiratory Research at Norwalk Hospital, Yale University School of Medicine) created an outstanding respiratory therapy department and an academic environment conducive to clinical investigation. Dr Nair's enthusiasm for new clinical concepts was contagious, and he consistently encouraged colleagues and fellows to challenge traditional norms. Second, in the months preceding our first attempt at NPPV, two visiting professors provided the seeds that germinated the concept of NPPV in ARF. Dr Omar Prakash (Erasmus University, Rotterdam, the Netherlands) expanded our understanding of the relatively new concept of pressure-cycled ventilation offered by the Siemens Servo 900 C ventilator, while Dr Dominique Robert (Hôpital de la Croix-Rousse, Lyon, France) reviewed the application of NPPV in patients with neuromuscular disease (as an alternative to mechanical ventilation [MV] via tracheostomy) for both long-term support and acute exacerbations, and generated interest in testing the applicability of NPPV in patients with ARF.
Third, an unforeseen opportunity arose. The first patient was a young woman with postchemotherapy pancytopenia who was admitted with sepsis and severe ARDS but refused intubation. The patient was initially placed on a Down C flow generator (based on the prior work of Greenbaum et al 3 ) and later switched to a Servo 900 C ventilator. The patient required a CPAP of 18 cm H 2 O and an FIO 2 of 0.7 to maintain adequate saturation. Two days later, the patient acutely deteriorated and was unable to maintain oxygenation despite increasing the FIO 2 to 100%. Thankfully, Dr Conoscenti (senior pulmonary fellow and former respiratory therapist) was quick to add pressure control (after a poor response with assist control), which was well tolerated and associated with a rapid and sustained improvement in gas exchange and work of breathing. After 4 days of NPPV, MV was removed, and the patient was discharged from the ICU and later from the hospital. The remarkable response surprised all and generated great enthusiasm in moving the concept forward. A few weeks later, a similar response was achieved in a young patient with Pneumocystis jirovecii pneumonia and severe ARDS.
These two cases were discussed at the monthly research conference. The general consensus was that young age and optimal nutritional status were significant factors behind the tolerance and response to NPPV in these two patients. Further, most clinical staff involved doubted its potential effectiveness in debilitated elderly patients with advanced COPD and acute exacerbation. They would be proven wrong. In the following months, six patients with severe COPD and hypercapnic ARF received NPPV. Three patients, lethargic from carbon dioxide retention, became alert and oriented after beginning NPPV. Clinical and physiologic improvements were seen shortly after beginning face mask ventilation (eg, a mean fall in respiratory rate of 18 breaths/min, and PaCO 2 of 18 mm Hg). NPPV duration was from 3 to 88 hours (mean, 31 hours). The mask was removed for brief periods of rest for the patients to receive nebulized bronchodilator treatment, drink water, expectorate secretions, or speak. Two patients with COPD died. Patient 3 refused to continue after 4 days of successful NPPV and died 15 hours after discontinuation. Patient 4 with oxygen-dependent COPD and severe coronary artery disease had an unexpected (autopsy-proven) acute myocardial infarction with cardiac arrest. A progress note recorded 30 minutes before the event by the junior pulmonary fellow (Dr Menashe) documented normal cardiopulmonary physiology and acceptable arterial blood gas levels. This documentation was essential to the continuation of the study. The two patients with ADHF experienced a rapid and sustained improvement in gas exchange after NPPV treatment.
Overall, the mean duration of NPPV was 33 hours (range, 3-88 hours). No patient left the study because of failure to achieve adequate oxygenation or ventilation. Only one patient (with ADHF) was eventually intubated because of intolerance of the mask. The only observed complication was the development of a nasal bridge abrasion at the mask application site, in two patients, that healed in a few days. On the basis of prior reports of gastric insufflation during NPPV in patients with chronic neuromuscular disease, a nasogastric tube on intermittent suction was inserted in all patients before initiating NPPV. One of the original article's reviewers correctly pointed out that the opening pressure of the resting upper esophageal sphincter is approximately 33 AE 12 mm Hg and below the peak positive pressure of NPPV. Future studies did not include routine placement of a nasogastric tube.
Eighteen months after the publication of our seminal paper, investigators in Paris published an elegant study evaluating the physiologic effects of inspiratory positive airway pressure delivered by means of a face mask in acute exacerbation of COPD. 4 This important work supported our prior findings and would inspire additional physiologic studies that improved our understanding of how (both continuous and intermittent) positive pressure delivered via a mask proportionally decreases the inspiratory threshold load and positively impacts the pathophysiology of both acute hypercapnic and hypoxemic ARF.
The mask available for our study was a snug-fitting anesthesia and respiratory air cushion mask (No. 8887; Hospitak Inc.) used in the operating room but less suitable for long-term use. For this reason, we contacted a small company near Pittsburg, Pennsylvania that had recently introduced masks and a CPAP machine for the treatment of sleep apnea. In several meetings with the founder and members of the company we shared our concerns about the available products and discussed modalities to improve them. Unfortunately, the company's verbal commitments to support research on NPPV failed to materialize despite the prospect of benefiting from the commercialization of new, NPPVrelated products.
Fortunately, following presentation of the data at the 54th Annual Scientific Assembly of the American College of Chest Physicians, Warren G. Sanborn, PhD, of Puritan Bennett expressed interest in this new approach and identified funding resources (Grant R07-33 40-67). This funding supported, among other things, a large observational study (n ¼ 164) investigating NPPV as the first-line intervention in a heterogeneous patient population with hypercapnic or hypoxemic ARF (including patients with postextubation ARF, or those not a candidate for invasive MV). 5 The foundation of the study was a systematic educational program (including lecture, posters, and video) for training physicians, using a simplified protocolized approach to NPPV (a combination of CPAP and pressure support ventilation guided by the findings of the new physiologic studies) under the guidance of an experienced respiratory therapist. This approach achieved a 65% success rate in avoiding intubation in a broad population of patients with hypercapnic ARF (acute exacerbation of COPD, status asthmaticus) and hypoxemic ARF (community-acquired pneumonia, Pneumocystis pneumonia, decompensated acute heart failure, ARDS). The results demonstrated the safety of NPPV under close observation, identified predictors of response, and provided a foundation for the design of future randomized trials investigating various conditions associated with ARF. 5 Thirty years ago, in an environment of academic freedom, established norms were challenged and the patients benefited.
